Effect of Cyclophosphamide on miRNA-15a expression in EBV infected transformed B cell

Authors
Abdolreza Sotoodeh Jahromi 1
Mohammad Kargar 1
Maliheh Moradzadeh 2
Farshid Kafilzadeh 1
Marzieh Jamalidoust 3
1 Department of microbiology, Jahrom branch, Islamic Azad University, Jahrom, Iran
2 Golestan rheumatolgy research cener, Sayad shirazi hospital, Golestan University of Medical Sciences, Gorgan, Iran
3 Clinical microbiology research center, Namazi hospital, Shiraz University of Medical Sciences, Shiraz, Iran
10.52547/jmj.19.1.2
Abstract
Introduction: Despite advances in diagnosis and therapy of cancer, it is still the main cause of death worldwide.
Cyclophosphamide is one of the major drugs for lymphoma treatment. However, the anti-lymphoma effects of cyclophosphamide on micro-RNA expression are still unclear, especially in B cell lymphomas. The aim of the present study was to evaluate the effect of cyclophosphamide on miRNA-15a genes expression in Epstein‐Barr‐Virus (EBV)-infected transformed B cell.
Materials and Methods: In this study, the effects of cyclophosphamide on CO 88BV59-1 LCL – an EBV infected transformed B cell was evaluated. The cells were treated with cyclophosphamide (0.05-50 μM), for 3 days. The cell
viability and cytotoxicity were evaluated using MTT, and flow cytometry techniques, respectively. Also, miRNA-15a genes expression were determined by real-time PCR.
Results: Cyclophosphamide significantly inhibited proliferation and induced cell death in the cell-line in a dose and time-dependent manner (P<0.05). There were no significant changes in the expression of miRNA-15a3p and miRNA-15a5p in treated cells compared to untreated cells (P>0.05).
Conclusions: The results showed that cytotoxic effects of cyclophosphamide on CO 88BV59-1 LCL is not related to
miRNA-15a3p and miRNA-15a5p expressions.
Keywords
Cyclophosphamide
Micro-RNA
B cell
Epstein Barr virus
1. Cohen JI. Epstein–Barr virus infection. New England Journal of Medicine. 2000;343(7):481-92. 2. Nijland ML, Kersten MJ, Pals ST, Bemelman FJ, ten Berge IJ. Epstein-Barr Virus–Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplantation direct. 2016;2(1). 3. Sakamoto K, Sekizuka T, Uehara T, Hishima T, Mine S, Fukumoto H, et al. Next‐generation sequencing of miRNAs in clinical samples of Epstein–Barr virus‐associated B‐cell lymphomas. Cancer medicine. 2017;6(3):605-18. 4. Hammond SM. An overview of microRNAs. Advanced drug delivery reviews. 2015;87:3-14. 5. Lewis BP, Shih I-h, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003;115(7):787-98. 6. Kole AJ, Swahari V, Hammond SM, Deshmukh M. miR-29b is activated during neuronal maturation and targets BH3-only genes to restrict apoptosis. Genes & development. 2011;25(2):125-30. 7. Wang Y, Medvid R, Melton C, Jaenisch R, Blelloch R. DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. Nature genetics. 2007;39(3):380. 8. Berindan‐Neagoe I, Monroig PdC, Pasculli B, Calin GA. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA: a cancer journal for clinicians. 2014;64(5):311-36. 9. Taganov KD, Boldin MP, Chang K-J, Baltimore D. NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proceedings of the National Academy of Sciences. 2006;103(33):12481-6. 10. Yoshino H, Yonemori M, Miyamoto K, Tatarano S, Kofuji S, Nohata N, et al. microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma. Oncotarget. 2017;8(13):20881. 11. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, et al. miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. International journal of cancer. 2008;123(2):372-9. 12. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences. 2005;102(39):13944-9. 13. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998;91(9):3379-89. 14. Huang E, Liu R, Chu Y. miRNA-15a/16: as tumor suppressors and more. Future oncology. 2015;11(16):2351-63. 15. Fu Q, He C, Mao Z-r. Epstein-Barr virus interactions with the Bcl-2 protein family and apoptosis in human tumor cells. Journal of Zhejiang University Science B. 2013;14(1):8-24. 16. Lanzkowsky P, Lipton JM, Fish JD. Lanzkowsky's manual of pediatric hematology and oncology: Academic Press; 2016. 17. Li Y, Liu S, Zhang F, Jiang P, Wu X, Liang Y. Expression of the microRNAs hsa-miR-15a and hsa-miR-16-1 in lens epithelial cells of patients with age-related cataract. International journal of clinical and experimental medicine. 2015;8(2):2405. 18. Yang L-h, Wang S-l, Tang L-l, Liu B, Wang L-l, Wang Z-y, et al. Universal stem-loop primer method for screening and quantification of microRNA. PLoS One. 2014;9(12):e115293. 19. Marques-Piubelli ML, Salas YI, Pachas C, Becker-Hecker R, Vega F, Miranda RN. Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: a review. Pathology. 2020;52(1):40-52. 20. Hu W, Kavanagh J. Anticancer therapy targeting the apoptotic pathway. The lancet oncology. 2004;4:721-9. 21. Cockram PE, Kist M, Prakash S, Chen S-H, Wertz IE, Vucic D. Ubiquitination in the regulation of inflammatory cell death and cancer. Cell Death & Differentiation. 2021:1-15. 22. Alonso-Castro AJ, Ortiz-Sánchez E, García-Regalado A, Ruiz G, Núñez-Martínez JM, González-Sánchez I, et al. Kaempferitrin induces apoptosis via intrinsic pathway in HeLa cells and exerts antitumor effects. J Ethnopharmacol. 2013;145(2):476-89. 23. Schwartz PS, Waxman DJ. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Molecular pharmacology. 2001;60(6):1268-79. 24. Vaisheva F, Delbes G, Hales BF, Robaire B. Effects of the chemotherapeutic Agents for Non‐Hodgkin Lymphoma, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), on the male rat reproductive system and progeny outcome. Journal of andrology. 2007;28(4):578-87. 25. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clinical Cancer Research. 2000;6(12):4950-6. 26. Musilova K, Mraz M. MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia. 2015;29(5):1004-17.